Cargando…

Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer

FAM13C, a gene with unknown function is included in several mRNA signatures for prostate cancer aggressiveness. To understand the impact of FAM13C on prognosis and its relationship to molecularly defined subsets, we analyzed FAM13C expression by immunohistochemistry on a tissue microarray containing...

Descripción completa

Detalles Bibliográficos
Autores principales: Burdelski, Christoph, Borcherding, Laura, Kluth, Martina, Hube-Magg, Claudia, Melling, Nathaniel, Simon, Ronald, Möller-Koop, Christina, Weigand, Philipp, Minner, Sarah, Haese, Alexander, Michl, Hans Uwe, Tsourlakis, Maria Christina, Jacobsen, Frank, Hinsch, Andrea, Wittmer, Corinna, Lebok, Patrick, Steurer, Stefan, Izbicki, Jakob R, Sauter, Guido, Krech, Till, Büscheck, Franziska, Clauditz, Till, Schlomm, Thorsten, Wilczak, Waldemar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458224/
https://www.ncbi.nlm.nih.gov/pubmed/28415558
http://dx.doi.org/10.18632/oncotarget.16357
_version_ 1783241715092553728
author Burdelski, Christoph
Borcherding, Laura
Kluth, Martina
Hube-Magg, Claudia
Melling, Nathaniel
Simon, Ronald
Möller-Koop, Christina
Weigand, Philipp
Minner, Sarah
Haese, Alexander
Michl, Hans Uwe
Tsourlakis, Maria Christina
Jacobsen, Frank
Hinsch, Andrea
Wittmer, Corinna
Lebok, Patrick
Steurer, Stefan
Izbicki, Jakob R
Sauter, Guido
Krech, Till
Büscheck, Franziska
Clauditz, Till
Schlomm, Thorsten
Wilczak, Waldemar
author_facet Burdelski, Christoph
Borcherding, Laura
Kluth, Martina
Hube-Magg, Claudia
Melling, Nathaniel
Simon, Ronald
Möller-Koop, Christina
Weigand, Philipp
Minner, Sarah
Haese, Alexander
Michl, Hans Uwe
Tsourlakis, Maria Christina
Jacobsen, Frank
Hinsch, Andrea
Wittmer, Corinna
Lebok, Patrick
Steurer, Stefan
Izbicki, Jakob R
Sauter, Guido
Krech, Till
Büscheck, Franziska
Clauditz, Till
Schlomm, Thorsten
Wilczak, Waldemar
author_sort Burdelski, Christoph
collection PubMed
description FAM13C, a gene with unknown function is included in several mRNA signatures for prostate cancer aggressiveness. To understand the impact of FAM13C on prognosis and its relationship to molecularly defined subsets, we analyzed FAM13C expression by immunohistochemistry on a tissue microarray containing 12,400 prostate cancer specimens. Results were compared to phenotype, ERG status, genomic deletions of 3p, 5q, 6q and PTEN, and biochemical recurrence. FAM13C was detectable in cell nuclei of cancerous and non-neoplastic prostate cells. 67.5% of 9,633 interpretable cancers showed FAM13C expression: strong in 28.3%, moderate in 24.6% and weak in 14.6%. Strong FAM13C expression was linked to advanced pT stage, high Gleason grade, positive lymph node status, and early biochemical recurrence (p < 0.0001 each). FAM13C expression was associated with TMPRSS2:ERG fusions. It was present in 85% of ERG positive but in only 54% of ERG negative cancers (p < 0.0001), and in 91.1% of PTEN deleted but in only 69.2% of PTEN non-deleted cancers (p < 0.0001). The prognostic role of FAM13C expression was independent of classical and quantitative Gleason grade, pT stage, pN stage, surgical margin status and preoperative PSA. In conclusion, the results of our study demonstrate that expression of FAM13C is an independent prognostic marker in prostate cancer. Finding FAM13C also in non-neoplastic prostate tissues highlights the importance of properly selecting cancer-rich areas for RNA-based FAM13C expression analysis.
format Online
Article
Text
id pubmed-5458224
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-54582242017-06-08 Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer Burdelski, Christoph Borcherding, Laura Kluth, Martina Hube-Magg, Claudia Melling, Nathaniel Simon, Ronald Möller-Koop, Christina Weigand, Philipp Minner, Sarah Haese, Alexander Michl, Hans Uwe Tsourlakis, Maria Christina Jacobsen, Frank Hinsch, Andrea Wittmer, Corinna Lebok, Patrick Steurer, Stefan Izbicki, Jakob R Sauter, Guido Krech, Till Büscheck, Franziska Clauditz, Till Schlomm, Thorsten Wilczak, Waldemar Oncotarget Research Paper FAM13C, a gene with unknown function is included in several mRNA signatures for prostate cancer aggressiveness. To understand the impact of FAM13C on prognosis and its relationship to molecularly defined subsets, we analyzed FAM13C expression by immunohistochemistry on a tissue microarray containing 12,400 prostate cancer specimens. Results were compared to phenotype, ERG status, genomic deletions of 3p, 5q, 6q and PTEN, and biochemical recurrence. FAM13C was detectable in cell nuclei of cancerous and non-neoplastic prostate cells. 67.5% of 9,633 interpretable cancers showed FAM13C expression: strong in 28.3%, moderate in 24.6% and weak in 14.6%. Strong FAM13C expression was linked to advanced pT stage, high Gleason grade, positive lymph node status, and early biochemical recurrence (p < 0.0001 each). FAM13C expression was associated with TMPRSS2:ERG fusions. It was present in 85% of ERG positive but in only 54% of ERG negative cancers (p < 0.0001), and in 91.1% of PTEN deleted but in only 69.2% of PTEN non-deleted cancers (p < 0.0001). The prognostic role of FAM13C expression was independent of classical and quantitative Gleason grade, pT stage, pN stage, surgical margin status and preoperative PSA. In conclusion, the results of our study demonstrate that expression of FAM13C is an independent prognostic marker in prostate cancer. Finding FAM13C also in non-neoplastic prostate tissues highlights the importance of properly selecting cancer-rich areas for RNA-based FAM13C expression analysis. Impact Journals LLC 2017-03-18 /pmc/articles/PMC5458224/ /pubmed/28415558 http://dx.doi.org/10.18632/oncotarget.16357 Text en Copyright: © 2017 Burdelski et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Burdelski, Christoph
Borcherding, Laura
Kluth, Martina
Hube-Magg, Claudia
Melling, Nathaniel
Simon, Ronald
Möller-Koop, Christina
Weigand, Philipp
Minner, Sarah
Haese, Alexander
Michl, Hans Uwe
Tsourlakis, Maria Christina
Jacobsen, Frank
Hinsch, Andrea
Wittmer, Corinna
Lebok, Patrick
Steurer, Stefan
Izbicki, Jakob R
Sauter, Guido
Krech, Till
Büscheck, Franziska
Clauditz, Till
Schlomm, Thorsten
Wilczak, Waldemar
Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer
title Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer
title_full Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer
title_fullStr Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer
title_full_unstemmed Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer
title_short Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer
title_sort family with sequence similarity 13c (fam13c) overexpression is an independent prognostic marker in prostate cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458224/
https://www.ncbi.nlm.nih.gov/pubmed/28415558
http://dx.doi.org/10.18632/oncotarget.16357
work_keys_str_mv AT burdelskichristoph familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT borcherdinglaura familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT kluthmartina familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT hubemaggclaudia familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT mellingnathaniel familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT simonronald familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT mollerkoopchristina familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT weigandphilipp familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT minnersarah familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT haesealexander familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT michlhansuwe familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT tsourlakismariachristina familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT jacobsenfrank familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT hinschandrea familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT wittmercorinna familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT lebokpatrick familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT steurerstefan familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT izbickijakobr familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT sauterguido familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT krechtill familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT buscheckfranziska familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT clauditztill familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT schlommthorsten familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer
AT wilczakwaldemar familywithsequencesimilarity13cfam13coverexpressionisanindependentprognosticmarkerinprostatecancer